Exact Sciences CORP 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Exact Sciences Corporation reported a 20% year-over-year revenue increase in Q3 2025, driven by strong Cologuard and Oncotype DX test volumes, alongside the launch of new cancer screening and diagnostic products.
Exact Sciences reported significant revenue growth and reduced net losses in Q2 2025, driven by Cologuard and Oncotype test adoption, while advancing its diagnostic pipeline and announcing a major collaboration with Freenome.
Exact Sciences Corporation announces an 11% increase in revenue for the first quarter of 2025, driven by growth in both screening and precision oncology segments.
Exact Sciences Corp. saw a 13% year-over-year revenue increase in the third quarter of 2024, driven by growth in Cologuard and Oncotype DX tests, while also achieving key milestones in its product pipeline.
Exact Sciences reports a strong second quarter with revenue growth, increased testing volumes, and progress in its pipeline development.
Exact Sciences saw a revenue increase in the first quarter of 2024, driven by growth in Cologuard and Oncotype DX tests, but the company still reported a net loss.